Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities (2014 - 2026)

Amphastar Pharmaceuticals' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 14.82% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 14.82% YoY), while the FY2025 annual figure was $5.9 million, down 14.82% from the prior year.
• Other Non-Current Liabilities was $5.9 million for Q1 2026 at Amphastar Pharmaceuticals, roughly flat from $5.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $27.8 million in Q2 2025 to a low of $5.9 million in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $12.8 million across 5 years, with a median of $7.2 million in 2022.
• Biggest YoY gain for Other Non-Current Liabilities was 358.23% in 2025; the steepest drop was 74.27% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $7.2 million in 2022, then soared by 214.44% to $22.7 million in 2023, then sank by 69.38% to $7.0 million in 2024, then dropped by 14.82% to $5.9 million in 2025, then changed by 0.0% to $5.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $5.9 million (Q1 2026), $5.9 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.